Free tool
FAERS Monitor: Xeomin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125360 or its brand name (Xeomin, Incobotulinumtoxina). Reports on generic versions are filed under their own applications.
Reports
5,818
Serious
787
14% of reports
Hospitalization
215
Death reported
110
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,876
- off label use1,218
- therapeutic response decreased761
- injection site pain343
- overdose237
- product preparation issue216
- injection site swelling213
- headache195
- product use in unapproved indication195
- pain181
- injection site erythema140
- eyelid ptosis134
- injection site mass134
- dysphagia127
- incorrect route of product administration115
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 2 |
| 2011 | 16 |
| 2012 | 66 |
| 2013 | 16 |
| 2014 | 20 |
| 2015 | 174 |
| 2016 | 354 |
| 2017 | 242 |
| 2018 | 368 |
| 2019 | 315 |
| 2020 | 394 |
| 2021 | 542 |
| 2022 | 555 |
| 2023 | 651 |
| 2024 | 830 |
| 2025 | 754 |
| 2026 | 519 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,341 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product preparation issueSignal | 216 | 123.1 | 107.7 | 25,181 |
| eyelid ptosisSignal | 134 | 48.3 | 40.8 | 6,081 |
| therapeutic response decreasedSignal | 761 | 45.9 | 43.0 | 33,086 |
| incorrect route of product administrationSignal | 115 | 24.4 | 20.4 | 2,543 |
| injection site massSignal | 134 | 13.1 | 11.1 | 1,489 |
| injection site swellingSignal | 213 | 10.1 | 8.8 | 1,734 |
| drug ineffectiveSignal | 1,876 | 5.2 | 5.0 | 6,683 |
| off label useSignal | 1,218 | 5.0 | 4.8 | 4,099 |
| dysphagiaSignal | 127 | 4.8 | 4.1 | 385 |
| injection site erythemaSignal | 140 | 4.1 | 3.5 | 324 |
| injection site painSignal | 343 | 4.0 | 3.7 | 794 |
| overdoseSignal | 237 | 4.0 | 3.5 | 530 |
| product use in unapproved indicationSignal | 195 | 2.8 | 2.5 | 234 |
| headache | 195 | 1.1 | 1.0 | 3 |
| pain | 181 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.